“…In their multivariate analysis only MNA retained independent predictive value for survival and PFS. Similar results for MAI and MNA were presented in other univariate and multivariate analyses (22,(43)(44)(45). Additionally, Baak and van Diest (20) showed that the combination of a low MAI and a low VPE was associated with an excellent 5-year OS probability for both early (91%) and advanced (100%) ovarian carcinoma.…”
supporting
confidence: 72%
“…4). Two other studies (17,43) presented strong associations of NP with survival and chemotherapy response. Baak and van Diest (20) found univariate prognostic significance for SD-MNA, MNA, MAI, VPE, and DNA ploidy.…”
The aim of this follow-up study is to validate the clinical significance of quantitative morphometric and DNA flow cytometric variables as independent prognostic factors of overall survival and progression-free survival in epithelial ovarian carcinoma. Tumor samples were collected from 135 patients with epithelial ovarian carcinoma at 3 hospitals in the Netherlands. Evaluated clinico-pathologic variables were age, histologic subtype, differentiation grade, clinical stage [International Federation of Gynecology and Obstetrics (FIGO)], presence of ascites, serum CA-125, and the completeness of debulking surgery. Morphometry and DNA flow cytometric techniques were assessed on each tumor sample to determine the mitotic activity index (MAI), volume percentage epithelium, mean nuclear area (MNA), standard deviation of MNA (SD MNA), nuclear perimeter (NP), and DNA ploidy. Univariate analysis showed that differentiation grade, FIGO stage, presence of ascites, preoperative CA-125 levels, DNA ploidy, and MAI, NP, and MNA were of significant prognostic value. After multivariate analysis (using forward Cox proportional hazard analysis), only differentiation grade and FIGO stage remained significant. From this study, we can conclude that morphometry and DNA flow cytometry are not independent prognosticators and therefore have no clinical value in predicting prognosis in ovarian carcinoma.
“…In their multivariate analysis only MNA retained independent predictive value for survival and PFS. Similar results for MAI and MNA were presented in other univariate and multivariate analyses (22,(43)(44)(45). Additionally, Baak and van Diest (20) showed that the combination of a low MAI and a low VPE was associated with an excellent 5-year OS probability for both early (91%) and advanced (100%) ovarian carcinoma.…”
supporting
confidence: 72%
“…4). Two other studies (17,43) presented strong associations of NP with survival and chemotherapy response. Baak and van Diest (20) found univariate prognostic significance for SD-MNA, MNA, MAI, VPE, and DNA ploidy.…”
The aim of this follow-up study is to validate the clinical significance of quantitative morphometric and DNA flow cytometric variables as independent prognostic factors of overall survival and progression-free survival in epithelial ovarian carcinoma. Tumor samples were collected from 135 patients with epithelial ovarian carcinoma at 3 hospitals in the Netherlands. Evaluated clinico-pathologic variables were age, histologic subtype, differentiation grade, clinical stage [International Federation of Gynecology and Obstetrics (FIGO)], presence of ascites, serum CA-125, and the completeness of debulking surgery. Morphometry and DNA flow cytometric techniques were assessed on each tumor sample to determine the mitotic activity index (MAI), volume percentage epithelium, mean nuclear area (MNA), standard deviation of MNA (SD MNA), nuclear perimeter (NP), and DNA ploidy. Univariate analysis showed that differentiation grade, FIGO stage, presence of ascites, preoperative CA-125 levels, DNA ploidy, and MAI, NP, and MNA were of significant prognostic value. After multivariate analysis (using forward Cox proportional hazard analysis), only differentiation grade and FIGO stage remained significant. From this study, we can conclude that morphometry and DNA flow cytometry are not independent prognosticators and therefore have no clinical value in predicting prognosis in ovarian carcinoma.
“…In advanced-stage (FIGO III-IV) epithelial ovarian cancer, MNA has shown to be a most important prognostic factor for survival in both univariate and multi-variate analysis (4,10,19,20) . SDNA (10,(19)(20)(21) , NP (10,21) , largest perpendicular axis (10,21) , longest axis (21) , and shortest axis (10) have also shown strong associations with survival.…”
Section: Discussionmentioning
confidence: 99%
“…Knowledge of predictive factors could lead to a better selection of patients who will benefit from aggressive therapy (4) . Morphometric data may not only be used to correlate with traditional tumor classification but also have been argued that morphometric data could be used as a prognostic parameter in survival and chemotherapy response (10) .…”
The objective of this study was to determine whether nuclear morphometric data can predict survival, disease progression, and chemotherapeutic response in ovarian serous carcinoma. Nuclear morphometric parameters were determined from archival hematoxylin and eosin sections of 132 serous tumors. Clinicopathologic and morphometric parameters were evaluated as to their individual and independent prognostic value and prediction of chemotherapy response. Nuclear parameters were found to strongly correlate with extent of disease residuum, tumor grade, and FIGO stage. Univariate analysis revealed stage, grade, preoperative CA125, presence of ascites, extent of disease residuum, standard deviation of nuclear area (SDNA), nuclear perimeter (NP), SDNP, nuclear length (NL), nuclear breadth (NB), orthoferet, and equivalent diameter (ED) to be significant predictors of overall survival (OS) and disease-free survival (DFS). Grade, stage, extent of disease residuum, presence of ascites, SDNA, NP, NL, NB, and orthoferet were found to be significant predictors of chemotherapy response. Multivariate analysis revealed extent of disease residuum (P
“…Brinkhuis et al in their study of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma, found the SD of the NA to be very significant parameter in a multivariate analysis [16]. Similarly, Baak et al and Katsoulis et al concluded that nuclear size is an important predictor of the sensitivity of tumor cells to cisplatin chemotherapy [14,17].…”
Objective: The main objectives of this study were: To evaluate nuclear major axis (MAJX) and minor axis (MINX), nuclear area (NA), nuclear perimeter (NP), nuclear aspect ratio (NAR), and nuclear roundness (NR) with their variability using morphometric techniques in malignant and benign ovarian tumors and to correlate them with histological grades. Methods: Morphometric parameters were evaluated in 8 low-grade (LG) and 22 high-grade (HG) serous ovarian carcinoma and 30 benign grade (BG) cases by digital image morphometric technique using histological sections. Results: The mean of the size-related nuclear parameters: MAJX, MINX, NA, NP, and their variability were statistically significantly greater (P < 0.01) in malignant cases than benign, whereas mean NAR and its variability were significantly lower in malignant cases. Mean NR was significantly higher but its variability (standard deviation -NR) was significantly lower in malignant cases. can be used to differentiate from benign with 100% efficiency. Conclusion: Morphometric parameters related to nuclear size and their variability were significantly larger in malignant cases than the benign and showed strong positive correlation with the grades. Nuclear shapes of the malignant nuclei were rounder than the benign. Nuclear morphometry can be gainfully exploited in the diagnosis of ovarian carcinoma quantitatively.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.